SY-5933

DRUG2 trials

Sponsors

Shouyao Holdings (Beijing) Co. LTD

Conditions

Advanced Solid Tumor

Phase 1

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Shouyao Holdings (Beijing) Co. LTDAdvanced Solid Tumor

Start: 2023-08-10End: 2025-08-15Target: 50Updated: 2023-09-01

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation

Not yet recruitingNCT06970132

Shouyao Holdings (Beijing) Co. LTDAdvanced Solid Tumor

Start: 2025-06-30End: 2028-12-31Target: 102Updated: 2025-05-14